CD8A and myeloid sarcoma: This study shows that OCR-treated MS patients exhibit a preserved recall response of CD8+ T cells following first vaccination compared to healthy controls (HCs) and a normal CD4+ Tfh1 and Th1 dynamics, whereas humoral and B cell responses were strongly impaired.